These correlations between Kindlin-2 expression and several clinicopathological parameters indicates that Kindlin-2 levels can be used as a marker to identify subsets of bladder cancer patients with more aggressive disease. The gene discussed is FERMT2; the disease is urinary bladder carcinoma.